Merck & Co. is enjoying a spurt of new drug launches, partly due to its $41 billion November acquisition of New Jersey neighbor Schering-Plough Corp. Some have been on the market in the United States for a while, including blockbuster diabetes medicine Januvia, and are now being launched in other countries.
| DRUG NAME | CONDITION/USE | WHERE IT’S LAUNCHING |
| Asmanex | Asthma | Japan |
| Bridion | Reversal of anesthesia | 30 countries outside the U.S. |
| Elonva | Fertility treatment | European Union |
| Januvia | Type 2 diabetes | Japan |
| Remeron | Depression | Japan |
| Saflutan | Glaucoma | European Union |
| Saphris | Schizophrenia/bipolar disorder | United States |
| Simponi | Immune disorders | 5 countries |
| Tredaptive | Hardening of the arteries | 27 countries outside the U.S. |
Date: May 25, 2010
Source: Associated Press
Filed Under: Drug Discovery
